New insider Mathew Marlyn Teresa claimed ownership of 129,182 units of Class A Ordinary Shares (SEC Form 3)
$ZURA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 04/17/2026 | 3. Issuer Name and Ticker or Trading Symbol
Zura Bio Ltd [ ZURA ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Class A Ordinary Shares | 129,182(1) | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Employee Share Option (Right to Buy) | (2) | 06/08/2032 | Class A Ordinary Shares | 37,505 | (3) | D | |
| Employee Share Option (Right to Buy) | (4) | 03/15/2033 | Class A Ordinary Shares | 11,133 | (5) | D | |
| Employee Share Option (Right to Buy) | (6) | 06/18/2034 | Class A Ordinary Shares | 90,000 | $3.38 | D | |
| Employee Share Option (Right to Buy) | (7) | 02/27/2035 | Class A Ordinary Shares | 81,150 | $1.2 | D | |
| Employee Share Option (Right to Buy) | (8) | 04/01/2036 | Class A Ordinary Shares | 66,220 | $6.03 | D | |
| Explanation of Responses: |
| 1. Includes 32,296 shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date. |
| 2. Immediately exercisable. |
| 3. $0.83732 |
| 4. One fourth (1/4) of the shares subject to the option award vested on March 15, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) monthly installments thereafter on the last day of the month, subject to the Reporting Person's continuous service through such vesting date. |
| 5. $1.19593 |
| 6. One fourth (1/4) of the shares subject to the option award vested on June 18, 2025 and the remaining shares subject to the option vested or shall vest in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| 7. One fourth (1/4) of the shares subject to the option award vested on February 27, 2026 and the remaining shares subject to the option vested or shall vest in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| 8. One fourth (1/4) of the shares subject to the option award shall vest on April 1, 2027 and the remaining shares subject to the option shall vest in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
| /s/ Kim Davis, Attorney-in-Fact | 06/22/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||